Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. H-CYTE, Inc.
  6. Summary
    HCYT   US4041241096

H-CYTE, INC.

(HCYT)
  Report
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Otc Markets
05/03/2021 05/04/2021 05/05/2021 05/06/2021 05/07/2021 Date
0.05(c) 0.0482(c) 0.04625(c) 0.0376(c) 0.033(c) Last
35 200 16 682 3 226 336 801 31 893 Volume
+6.38% -3.60% -4.05% -18.70% -12.23% Change
More quotes
Financials (USD)
Sales 2019 8,35 M - -
Net income 2019 -29,8 M - -
Net Debt 2019 1,47 M - -
P/E ratio 2019 -0,38x
Yield 2019 -
Sales 2020 2,15 M - -
Net income 2020 -6,46 M - -
Net cash position 2020 0,47 M - -
P/E ratio 2020 -0,27x
Yield 2020 -
Capitalization 4,52 M 4,52 M -
EV / Sales 2019 1,72x
EV / Sales 2020 0,75x
Nbr of Employees -
Free-Float 20,1%
More Financials
Company
H-CYTE, Inc., formerly Medovex Corp., is a development-stage company. The Company focuses on obtaining, developing and commercializing various intellectual property rights (patents, patent applications and knowhow) in the medical technology area, with particular focus on the development of medical devices. It focuses on the development and commercialization of the DenerveX System, which consists of the DenerveX... 
More about the company
All news about H-CYTE, INC.
04/08H-CYTE, INC.  : Entry into a Material Definitive Agreement, Financial Statements..
AQ
04/07H-CYTE, INC.  : Entry into a Material Definitive Agreement, Creation of a Direct..
AQ
03/25H CYTE  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
01/19H-CYTE, INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
2020H CYTE  : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2020H-CYTE, INC.  : Entry into a Material Definitive Agreement, Change in Directors ..
AQ
2020H CYTE  : Robert Greif named Chief Executive Officer of H-CYTE
AQ
2020Robert Greif named Chief Executive Officer of H-CYTE
GL
2020H-CYTE, INC.  : Unregistered Sale of Equity Securities, Other Events (form 8-K)
AQ
2020H-CYTE EXTENDS RIGHTS OFFERING TO 5 : 00 PM Eastern Time on Friday, September 11..
GL
2020H-CYTE, INC.  : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
2020H-CYTE EXTENDS RIGHTS OFFERING TO 5 : 00 PM Eastern Time on Friday, September 11..
GL
More news
News in other languages on H-CYTE, INC.

- No features available -

More news
Chart H-CYTE, INC.
Duration : Period :
H-CYTE, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Robert Greif President & Chief Executive Officer
Jeremy Daniel Chief Financial & Accounting Officer
Raymond Monteleone Chairman
Tanya Rhodes Chief Technology Officer
William E. Horne Director
Sector and Competitors
1st jan.Capitalization (M$)
H-CYTE, INC.102.58%5
ABBOTT LABORATORIES8.49%211 068
MEDTRONIC PLC8.67%171 610
BECTON, DICKINSON AND COMPANY-4.33%69 970
ALIGN TECHNOLOGY, INC.11.97%46 273
HOYA CORPORATION-7.88%44 850